Choriocarcinoma
ICD-10 C58 · ICD-11 2C75.0

High-Risk Gestational Choriocarcinoma (WHO Score ≥7): What to Do When EMA-CO Has Not Normalized Serum hCG

Clinical Scenario
HIGH RISK — WHO SCORE ≥7

This protocol applies to patients diagnosed with gestational choriocarcinoma whose WHO modified prognostic index score for gestational trophoblastic neoplasm (GTN) is 7 or higher, placing them in the high-risk category. Patients reaching this score threshold require multi-agent chemotherapy.

When the First-Line Regimen Has Not Reached Its Goals

The standard first-line approach for high-risk gestational choriocarcinoma is EMA-CO (etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine). Its primary endpoint is normalization of serum human chorionic gonadotropin (hCG) — confirmed by normal serum hCG on three consecutive weekly measurements.

This protocol addresses the clinical situation in which EMA-CO has not achieved sustained hCG normalization, or where a further treatment step is needed after an initial response, and escalation to the next line is required.

Next-Line Treatment Approach

The recommended next step is salvage chemotherapy with a specific multi-agent combination, which may be administered with or without excision of any persistent tumor. The full regimen, eligibility criteria, and clinical considerations are detailed in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ijgc-2023-004704

Patients with gestational choriocarcinoma who reach a WHO modified prognostic index score for GTN of 7 or higher should initially be treated with multi-agent chemotherapy.

Consider using single-agent chemotherapy in low-risk (score <7) and multi-agent chemotherapy in high risk (score of 7 or more).

EMA-EP is considered the most appropriate second line regimen as illustrated by several investigations on this issue.

Salvage chemotherapy including etoposide and platinum (with or without excision of the persistent tumor) is associated with excellent cure rates (80–90%).

Consider the EMA-EP regimen in women who have responded to EMA-CO.

View source ↗